Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Research in Real-Life Ltd
With
Napp Pharmaceuticals Limited
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Able and willing to provide written informed consent and to comply with the study protocol.
Current diagnosis of asthma (as evidenced by appropriate diagnostic code)
Received Seretide® 250 Evohaler® 2 puffs twice daily for the last 6 months
No asthma exacerbation\* in last 3 months
≤2 exacerbations\* in last 12 months
No errors in device use after training (during baseline visit)
Women of childbearing potential (not surgically sterile or 2 years postmenopausal) must use a medically accepted method of contraception and must agree to continue use of this method for the duration of the study and for 30 days after discontinuation of study drug. Acceptable methods of contraception include intrauterine device (IUD) known to have a failure rate of less than 1% per year, steroidal contraceptive (oral, implanted, transdermal, or injected), barrier method with spermicide, abstinence, and partner vasectomy.
* Exacerbation defined as acute course of oral steroids, emergency room attendance and/or hospitalisation for asthma
You may not be if
Other chronic respiratory disease than asthma (e.g. Chronic Obstructive Pulmonary Disease (COPD))
Uncontrolled asthma (GINA criteria)
The patient has used a clinical trial investigational drug within the last year before the screening visit
Hypersensitivity to Flutiform®, its component Formoterol or its excipients
Pregnant subjects
Clareo Health | A Guideline Approach to Therapy Step-down Utilising Flutiform Change and Step-down
